Yet another study including 899 patients investigated the long-term efficacy and safety of Empagliflozin monotherapy compared with placebo and sitagliptin (a dipeptidyl peptidase-4 inhibitor) in the drug naïve patients with T2DM. Here, DPP4 is linked to type 2 diabetes mellitus.